James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Medical Devices: 5 Healthcare Stocks to Buy

If President Obama's new tax on medical devices was supposed to be a problem for healthcare equipment makers, you wouldn't know it from these five companies.

Amazon Earnings Preview: Can New Projects Boost AMZN Stock?

When the Amazon earnings results for Q4 come out on Thursday afternoon, current and potential AMZN stock owners will be scrutinizing these key initiatives.

Gold Prices Start 2014 on the Right Foot, But Don’t Get Used to It

This year has been a good one for gold prices and gold miners, offering a reprieve from a miserable 2013. But the longer-term drags on gold remain intact.

BMY Pummeled After Earnings, But Bristol-Myers Squibb Stock Still a Buy

Bristol-Myers Squibb stock has a lot going for it, like the company's newfound focus on hepatitis C, oncology and immunotherapy. But BMY still might need time to reflect that potential.

EBAY Stock: Sorry, Carl Icahn, But a PayPal Spinoff Only Helps You

Just because Carl Icahn says EBAY stock is better served by a spinoff of PayPal doesn't mean it's best for all eBay investors.

More U.S. Companies Realize China Isn’t Worth the Trouble

The oft-ballyhooed growth opportunities in China are proving to be little more than pipedreams for U.S. corporations, for a growing list of reasons.

EXPE: Expedia Has More to Fear Than the Google Penalty Box

Google rankings are a big deal for any company with a website, but there's something else that should keep EXPE stock investors up at night.

5 Tech Stocks With Electric Dividend Yields

Tech stocks aren't usually known for generating income, but that doesn't mean there aren't a few juicy dividend yields in the lot.

5 Biotech Stocks With Big Catalysts on the Horizon

Announcements from, or about, these biotech stocks could greatly inflate their values ... or completely deflate them.

5 Electric Vehicle Stocks to Buy Now … That Aren’t Tesla

Tesla has become the iconic name in the electric vehicle world, but there are lots of other stocks to buy in the EV arena. Here are five of the hottest.